Marks JD - Search Results

1

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Cao Y, et al. Among authors: marks jd, marks jw. Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16. Mol Cancer Ther. 2012. PMID: 22090420

2

Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.

Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Cao Y, et al. Among authors: marks jd, marks jw. Cancer Res. 2009 Dec 1;69(23):8987-95. doi: 10.1158/0008-5472.CAN-09-2693. Epub 2009 Nov 24. Cancer Res. 2009. PMID: 19934334

3

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Rudnick SI, et al. Among authors: marks jd. Cancer Res. 2011 Mar 15;71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277. Cancer Res. 2011. PMID: 21406401 Free PMC article.

4

Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.

Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Zhou Y, et al. Among authors: marks jd. Mol Cancer Ther. 2012 Jul;11(7):1467-76. doi: 10.1158/1535-7163.MCT-11-1038. Epub 2012 May 7. Mol Cancer Ther. 2012. PMID: 22564724 Free PMC article.

5

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

Nielsen UB, Adams GP, Weiner LM, Marks JD. Nielsen UB, et al. Among authors: marks jd. Cancer Res. 2000 Nov 15;60(22):6434-40. Cancer Res. 2000. PMID: 11103810

6

Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Zhou Y, et al. Among authors: marks jd. J Mol Biol. 2007 Aug 24;371(4):934-47. doi: 10.1016/j.jmb.2007.05.011. Epub 2007 May 10. J Mol Biol. 2007. PMID: 17602702 Free PMC article.

7

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 2001 Jun 15;61(12):4750-5. Cancer Res. 2001. PMID: 11406547

8

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Adams GP, et al. Among authors: marks jd. Br J Cancer. 1998 May;77(9):1405-12. doi: 10.1038/bjc.1998.233. Br J Cancer. 1998. PMID: 9652755 Free PMC article.

9

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.

Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 2004 Sep 1;64(17):6200-6. doi: 10.1158/0008-5472.CAN-03-2382. Cancer Res. 2004. PMID: 15342405

10

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 1998 Feb 1;58(3):485-90. Cancer Res. 1998. PMID: 9458094

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters